Exploring the recovery phase after treatment with a gonadotrophin-releasing hormone-agonist for ovulation induction in polycystic ovary syndrome: three pilot trials.
OBJECTIVE
Guided by the favorable results of pulsatile gonadotrophin-releasing hormone (GnRH) in the recovery phase after GnRH agonist (GnRH-a) in PCOS, two hypotheses concerning the recovery phase were tested: (1) The resistance to clomiphene citrate will be broken in the recovery phase. (2) Stimulation with (i) a fixed dose of follicle stimulating hormone (FSH) or (ii) with the GnRH-a itself is equally effective in inducing ovulation as pulsatile GnRH.


METHODS
After discontinuation of a 17-21 days GnRH-a treatment, ovulation induction was attempted with clomiphene citrate (CC) or with a fixed dose of FSH or with GnRH-a itself in three separate pilot trials. A previously reported group of 12 patients, treated with pulsatile GnRH in the recovery phase served as control.


METHODS
Three groups of six patients having PCOS. The group treated with CC was a selected CC-resistant group.


RESULTS
No CC-treated patient ovulated. After FSH stimulation two patients ovulated, and one patient ovulated on stimulation with a low dose of the GnRH-a. Endocrine observations in the recovery phase showed an early rise of FSH as compared to the rise of LH and androgens.


CONCLUSIONS
This study could not demonstrate any effect of the recovery phase with respect to facilitation of follicular growth in PCOS. Both tested hypotheses were rejected: (1) The resistance to CC appeared not to be broken by the GnRH-a treatment and (2) subsequent stimulation with FSH or with the GnRH-a itself were not as effective as stimulation with pulsatile GnRH. An extensive further study of the mentioned modalities did not seem feasible.
Scheele
F
F
Department of Obstetrics and Gynaecology, Diakonessenhuis, Utrecht, The Netherlands.
van der Meer
M
M
Lambalk
C B
CB
Schoute
E
E
Schoemaker
J
J
Hompes
P G
PG
D000328:Adult; D002996:Clomiphene / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005240:Feasibility Studies; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D010062:Ovulation Induction / Q000379:methods*; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D013268:Stimulation, Chemical
D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone